share_log

開拓藥業-B：年報 2023

KINTOR PHARMA-B: ANNUAL REPORT 2023

Hong Kong Stock Exchange ·  Apr 29 00:11
Summary by Moomoo AI
金斗雲藥業有限公司於2023年12月31日年度報告中宣布，公司當年度淨虧損約為人民幣1060.8百萬元。公司總資產為人民幣869.2百萬元，總負債則為人民幣411.1百萬元。該年度公司未有產品銷售收入，但收到政府補助共人民幣8.7百萬元，以補償研發開支。普華永道對公司財務報表進行審計，未發現重大錯報。金斗雲藥業自2020年5月22日起在香港聯合交易所主板上市。公司的財務風險管理包括市場風險、信用風險和流動性風險，除了財富管理產品和外幣期權外，沒有重大的按公允價值計量的金融資產或負債。由於大部分交易以人民幣結算，公司沒有顯著的外匯風險。公司根據資本結構比率監控資本，由於現金及現金等價物超過總借款...展開全部
金斗雲藥業有限公司於2023年12月31日年度報告中宣布，公司當年度淨虧損約為人民幣1060.8百萬元。公司總資產為人民幣869.2百萬元，總負債則為人民幣411.1百萬元。該年度公司未有產品銷售收入，但收到政府補助共人民幣8.7百萬元，以補償研發開支。普華永道對公司財務報表進行審計，未發現重大錯報。金斗雲藥業自2020年5月22日起在香港聯合交易所主板上市。公司的財務風險管理包括市場風險、信用風險和流動性風險，除了財富管理產品和外幣期權外，沒有重大的按公允價值計量的金融資產或負債。由於大部分交易以人民幣結算，公司沒有顯著的外匯風險。公司根據資本結構比率監控資本，由於現金及現金等價物超過總借款，因此此比率不適用。公司未提前採用任何自2023年1月1日財政年度開始尚未生效的新準則和解釋。公司的關鍵會計估計和判斷包括開發支出、尚未準備好使用的無形資產的減值測試、存貨準備和固定資產的使用壽命。公司董事會負責根據國際財務報告準則和香港公司條例的披露要求，準備綜合財務報表。
JINDOYUAN PHARMACEUTICAL CO., LTD. ANNOUNCED IN ITS ANNUAL REPORT ON DECEMBER 31, 2023 THAT THE COMPANY'S NET LOSS FOR THE YEAR WAS APPROXIMATELY RMB1060.8 MILLION. The total assets of the company are RMB869.2 million and total liabilities are RMB411.1 million. The company had no revenue from product sales for the year, but received a total of RMB8.7 million in government subsidies to compensate for research and development expenses. PwC audited the company's financial statements and found no significant errors. Gold Dou Wan Pharmaceuticals has been listed on the main board of the Hong Kong Stock Exchange since 22 May 2020. The company's financial risk management includes market risk, credit risk and liquidity risk, with the exception of wealth management products and foreign currency options, with...Show More
JINDOYUAN PHARMACEUTICAL CO., LTD. ANNOUNCED IN ITS ANNUAL REPORT ON DECEMBER 31, 2023 THAT THE COMPANY'S NET LOSS FOR THE YEAR WAS APPROXIMATELY RMB1060.8 MILLION. The total assets of the company are RMB869.2 million and total liabilities are RMB411.1 million. The company had no revenue from product sales for the year, but received a total of RMB8.7 million in government subsidies to compensate for research and development expenses. PwC audited the company's financial statements and found no significant errors. Gold Dou Wan Pharmaceuticals has been listed on the main board of the Hong Kong Stock Exchange since 22 May 2020. The company's financial risk management includes market risk, credit risk and liquidity risk, with the exception of wealth management products and foreign currency options, with no significant financial assets or liabilities measured at fair value. Since most transactions are settled in RMB, the company has no significant foreign exchange risk. The Company monitors capital based on the Capital Structure Ratio. As cash and cash equivalents exceed total borrowings, this ratio is not applicable. The Company has not adopted any new guidelines and interpretations that have not been in effect since the fiscal year began on January 1, 2023. Key accounting estimates and determinations of the company include development expenses, depreciation testing of intangible assets that are not yet ready for use, inventory preparation, and the useful life of fixed assets. The Board of Directors is responsible for preparing consolidated financial statements in accordance with the disclosure requirements of the International Financial Reporting Standards and the Hong Kong Companies Ordinance.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more